Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Gilead Sciences Inc(GILD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GILD
11/11/2026: GILD (5-star) is a STRONG-BUY. BUY for 89 days. Simulated Profits (26.59%). Updated daily EoD!
Gilead Sciences is a major biopharmaceutical company with a dominant, historically profitable position in HIV and virology treatments. The company's core strength lies in its established cash-generating franchises and strong operating margins. Investors generally focus on Gilead's ongoing efforts to diversify into oncology to drive future growth, though this transition faces execution risks and intense competitive pressure. The stock is often viewed as a defensive value play, supported by a consistent, reliable dividend. Investors should monitor clinical trial progress in the oncology pipeline and the impact of evolving healthcare policy on drug pricing as key factors influencing the company's long-term outlook.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Gilead offers growth potential in oncology but is currently balancing this against maturing legacy franchises. |
| Momentum investor | Weak fit | The stock often experiences extended consolidation periods and is not typically driven by short-term momentum. |
| Value investor | Strong fit | With steady cash flows and a reasonable valuation, the stock often appeals to investors seeking defensive value in biotech. |
| Dividend investor | Strong fit | Gilead provides a reliable, growing dividend yield that is attractive for income-focused healthcare investors. |
| Low-risk investor | Medium | While established, the company faces inherent biotech risks such as clinical trial failures and regulatory hurdles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biotech stocks are sensitive to clinical trial results and regulatory news, which can cause sudden price swings. |
| Valuation risk | Low | The company generally trades at moderate multiples relative to high-growth peers. |
| Competition risk (virology/oncology) | Medium / high | New entrants and generic versions of existing drugs pose a constant threat to market share. |
| Business quality | Strong | Gilead possesses a high-quality portfolio with strong margins and deep scientific expertise. |
| Dividend income | Low | The dividend is well-supported by current cash flows and carries minimal risk of suspension. |
| Execution risk | Medium | The successful integration of recent oncology acquisitions and pipeline delivery is critical for future performance. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 88.01% | Avg. Invested days 61 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/11/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 211.94B USD | Price to earnings Ratio - | 1Y Target Price 174.77 |
Price to earnings Ratio - | 1Y Target Price 174.77 | ||
Volume (30-day avg) 6.4M shares | Beta 0.37 | 52 Weeks Range 114.81 - 176.58 | Updated Date 11/11/2026 |
52 Weeks Range 114.81 - 176.58 | Updated Date 11/11/2026 | ||
Dividends yield (FY) 1.92% | Basic EPS (TTM) -3.13 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Virology | HIV products like Biktarvy and Descovy, and HCV products like Epclusa. | This is the company's core cash-cow segment, generating the majority of profits. |
| Oncology | Cell therapies (Yescarta) and solid tumor drugs (Trodelvy). | This is the primary growth engine for the future, representing the company's expansion into new cancer treatments. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 2.17 | Actual 2.55 |
Profitability
Profit Margin -12.46% | Operating Margin (TTM) 42.43% |
Management Effectiveness
Return on Assets (TTM) 13.47% | Return on Equity (TTM) -22.45% |
Valuation
Trailing PE - | Forward PE 17.15 | Enterprise Value 231.73B | Price to Sales(TTM) 6.84 |
Enterprise Value 231.73B | Price to Sales(TTM) 6.84 | ||
Enterprise Value to Revenue 7.42 | Enterprise Value to EBITDA 177.73 | Shares Outstanding 1.24B | Shares Floating 1.24B |
Shares Outstanding 1.24B | Shares Floating 1.24B | ||
Percent Insiders 0.11 | Percent Institutions 92.14 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.